European Respiratory Society (ERS) International Congress 2019

Bronchial thermoplasty shows sustained efficacy in asthma

Audrey Abella, 20191022100000

Bronchial thermoplasty (BT) provided sustained improvements in patients with severe asthma, according to the results of the BT10+* study presented at ERS 2019.

As-needed budesonide-formoterol a PRACTICAL option for mild-to-moderate asthma

Pearl Toh, 20191017190000

As-needed budesonide–formoterol (ICS* + LABA**) reliever therapy was more effective than maintenance low-dose budesonide plus as-needed terbutaline (maintenance ICS + as-needed SABA***) for preventing severe exacerbations in patients with mild-to-moderate asthma, according to the PRACTICAL study presented at ERS 2019.

Prophylactic azithromycin may reduce exacerbations in primary antibody deficiencies

Roshini Claire Anthony, 20191016140101

Antibiotic prophylaxis with azithromycin in individuals with primary antibody deficiencies (PAD) may lead to a reduced risk of respiratory exacerbations, according to a phase II trial presented at ERS 2019.

Antibiotic use may not be necessary in COPD patients with nonpurulent exacerbation

Stephen Padilla, 20191016120000

Treatment without antibiotic medication does not appear to be inferior to moxifloxacin therapy as regards treatment failure or length of stay (LOS) among patients with chronic obstructive pulmonary disease (COPD) requiring hospitalization for nonpurulent exacerbation, according to the results of a study presented at the European Respiratory Society (ERS) International Congress 2019.

Unnecessary use of high-dose oral steroids prevalent in patients with severe asthma

Pearl Toh, 20191014190000

About one-third of patients with severe asthma who are on high-dose inhaled corticosteroids (ICS) are also receiving excessive doses of oral corticosteroids (OCS), reveals a study presented at the ERS 2019 Meeting.

Endobronchial valve improves symptoms, QoL in patients with emphysema

Audrey Abella, 20191014100000

Use of the Zephyr endobronchial valve (EBV) led to significant improvements in a range of patient-reported outcomes (PROs) including multiple domains of respiratory symptoms and quality of life (QoL) in patients with severe emphysema, according to the post hoc results of the LIBERATE* trial presented at ERS 2019.

Dr Helene Kobbernagel expounds on the role of azithromycin in primary ciliary dyskinesia in the BESTCILIA trial.

20191014072359

Dr Helene Kobbernagel expounds on the role of azithromycin in primary ciliary dyskinesia in the BESTCILIA trial.

Prof Giorgio Walter Canonica talks about the importance of triple therapy in a single inhaler device for patients with asthma.

20191014071617

Prof Giorgio Walter Canonica talks about the importance of triple therapy in a single inhaler device for patients with asthma.

Highlights From European Respiratory Society (ERS) International Congress 2019

20191014032226

Highlights From European Respiratory Society (ERS) International Congress 2019

REALITI-A shows mepolizumab effectiveness in severe asthma

Mepolizumab effectiveness a REALITI in severe eosinophilic asthma

Roshini Claire Anthony, 20191012100301

Preliminary real-world findings of the REALITI-A* study, presented at ERS 2019, have demonstrated a significant reduction in asthma exacerbations with mepolizumab, a result comparable to that of regulatory clinical trials with this drug.